Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8... (

Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion

Date:4/9/2008

- Acquisition Accelerates Takeda's Vision of Becoming a Global Leader in

Oncology -

OSAKA, Japan, and CAMBRIDGE, Mass., April 10 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that they have entered into a definitive agreement pursuant to which Takeda will acquire Millennium for approximately $8.8 billion through a cash tender offer of $25.00 per share. The transaction was unanimously approved by the Boards of Directors of both companies. Upon completion of the acquisition, Millennium will become a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, and will continue operations in Cambridge, Massachusetts, as a standalone business unit. Millennium will be known as Millennium Pharmaceuticals, Inc., a Takeda Company.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

Millennium is a leading biopharmaceutical company. In the United States, Millennium markets VELCADE(R) (bortezomib) for Injection-a novel, market- leading oncology product approved in more than 85 countries. Millennium has an innovation-driven discovery and development organization, which is advancing a pipeline of novel product candidates in oncology and inflammation. This includes a potential therapy for inflammatory bowel disease (IBD), which is expected to enter Phase III clinical trials in late 2008/early 2009. Millennium reported total revenues of approximately $528 million for 2007.

The acquisition of Millennium accelerates Takeda's vision of becoming a global leader in oncology with critical mass in
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. PPD Confirms Takedas NDA Filing of Alogliptin with U.S. Food and Drug Administration
2. Affymax(R) and Takeda Recognized for Innovative Global Agreement to Develop and Commercialize Hematide(TM) for Anemia
3. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
4. VWR International, LLC Acquires Jencons (Scientific) Ltd, UK
5. Aida Pharmaceuticals, Inc. Acquires High-Level Research Institute in the Peoples Republic of China
6. Aida Acquires High-Level Research Institute in China
7. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
8. China Aoxing Pharmaceutical Company Signed Definitive Acquisition Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Company, Ltd.
9. Immucor To Acquire BioArray Solutions Ltd.
10. Mindray to Acquire Datascopes Patient Monitoring Business for US$202 million
11. Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company

Post Your Comments:

Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8...( - Acquisition Accelerates Takeda's ...)